Evaluation of the value of plasma concentration of copeptin in the first prenatal visit to diagnose gestational diabetes mellitus

• Published in: Acta diabetologica 2017-12, Vol.54 (12), p.1123-1129
• Main Authors: Ma, He-hong, Yang, Shuang-yan, Wang, Pei, Zhang, Jun-Feng
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers - blood; Blood Glucose - analysis; Cohort Studies; Diabetes; Diabetes mellitus; Diabetes, Gestational - blood; Diabetes, Gestational - diagnosis; Early Diagnosis; Female; Gestation; Glucose tolerance; Glucose Tolerance Test; Glycopeptides - blood; Humans; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Obstetrics; Office Visits; Original Article; Peptides; Predictive Value of Tests; Pregnancy; Prenatal Care - methods; Prenatal Diagnosis - methods; Prognosis; Reclassification; Risk Factors; Young Adult
• ISSN: 0940-5429; 1432-5233
• DOI: 10.1007/s00592-017-1058-y

Aims Gestational diabetes mellitus (GDM) is increasing worldwide. The aim of this study was to investigate whether copeptin concentrations, measured at the first prenatal visit, are associated with risk of GDM. Methods From July 2015 to June 2016, consecutive women who admitted to the obstetrics center of our hospital were included. Data for fasting plasma glucose and copeptin concentrations at the first prenatal visit and one-step GDM screening with 75-g oral glucose tolerance test performed between 24 and 28 weeks of gestation were collected and analyzed. The relationship between levels of copeptin and GDM were evaluated using univariate and multivariate regression analysis. Results In this study, 101 out of the 827 women developed GDM (12.2%). The GDM distribution across the copeptin quartiles ranged between 4.4% (first quartile) and 25.1% (fourth quartile). For each 1 log-unit increase in plasma concentration of copeptin, the unadjusted and adjusted risk of GDM increased by 1442% (odds ratio 15.42 [95% CI 3.35–54.25], P